Search results for: 'Defense Data Analytics, Machine Learning, and Artificial Intelligence Growth Opportunities'

13 Jun 2023  |  North America  |  Market Research

US Healthcare Data Analytics, 2023

Competitive Intensity is Driving Innovation Among Healthcare Data Analytics Vendors

Infographics

×

This report offers a comprehensive analysis of the US healthcare data analytics market. The analysis focuses on solutions for payers and providers (including physician practices and hospitals). Solutions for the life sciences segment, pharmaceutical companies, and the public sector have been excluded. This study categorizes healthcare data analytic...

The medical imaging and informatics industry is evolving, with vendors launching new products and solutions every other day. As the reimbursement environment transitions from fee-for-service to value-based payment, vendors business models and value propositions are changing. New evidence on the use of specific imaging techniques is influencing chan...

19 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: Healthcare Data Analytics, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Healthcare organizations must be able to manage, analyze, and interpret data in order to identify strategic, tactical, and operational insights for decision making. This allows providers and payers to provide the best ways of delivering high-quality care. There has been a slow but steady change in the healthcare industry at the very core of its bus...

01 Jun 2020  |  North America  |  Market Research

Growth Opportunities in Artificial Intelligence and Analytics in Surgery, 2020

Landscape and Opportunity Assessment in an Emerging Area

Infographics

×

Key Issues Addressed

Artificial intelligence (AI) and analytics technologies are now being well accepted in healthcare, with bellwether clinical application areas (e.g., radiology), and operational application areas (e.g., revenue cycle management). One area of the hospital that perhaps needs the most attention, is the hospital operating room (OR). The OR is a hospital...

Frost & Sullivan research found the visible market success of artificial intelligence (AI)-driven interactive virtual assistants (IVAs), such as Alexa from Amazon and the Google Assistant, has been matched by specialized IVA deployments in various vertical markets such as financial services, education, and retail. Healthcare has presented opportun...

Clinical genomics regained significance during the pandemic with the development of the mRNA COVID-19 vaccine, and several non-invasive at-home test kits; an unprecedented feat in recent times. Genomics will take center stage, as large genome sequencing and research will continuously create data for new therapeutics. Artificial Intelligence (AI) an...

Biomarker Analytics has always been one of the most in-demand branches of science relevant to the process of drug discovery and development in the Pharmaceutical Industry. Over the years several advances have been made in the area of biomarker analytics with the aim to accelerate the drug development process. The use of AI-based technology can incr...

As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution. Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs...

25 Apr 2022  |  North America  |  Frost Radar

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phase...